(Q45227676)

11 December 2017

title

Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection (English)

1 reference

11 December 2017

1 reference

1 reference

Collier JD

1

1 reference

11 December 2017

Woodall T

2

1 reference

11 December 2017

Wight DG

3

1 reference

11 December 2017

Shore S

4

1 reference

11 December 2017

Gimson AE

5

1 reference

11 December 2017

Alexander GJ

6

1 reference

11 December 2017

publication date

1 January 2005

1 reference

Journal of Viral Hepatitis

11 December 2017

published in

1 reference

11 December 2017

volume

12

1 reference

11 December 2017

issue

1

1 reference

11 December 2017

page(s)

74-80

1 reference

The prevalence of hepatitis C in England and Wales.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Importance of age in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Host genetic factors influence disease progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Morbidity of chronic hepatitis C as seen in a tertiary care medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Role of alcohol in the progression of liver disease caused by hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Steatosis and intrahepatic hepatitis C virus in chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00598.X

10.1111/J.1365-2893.2005.00598.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference